The urinary antibacterial and antiseptic pharmaceuticals market is likely to register a CAGR of 4.3% during the forecast period. The market is estimated to be valued at US$ 44.2 Bn in 2022 and likely to be valued at US$ 67.34 Bn by 2032.
Urinary Antibacterial and Antiseptic Pharmaceuticals Market CAGR (2022-2032)
Urinary Antibacterial and Antiseptic Pharmaceuticals Market Value (2022)
US$ 44.2 Bn
Urinary Antibacterial and Antiseptic Pharmaceuticals Market Value (2032)
US$ 67.34 Bn
The growing urinary infections in the areas such as the urethra, bladder, kidney, and ureters are likely to upsurge the urinary antibacterial and antiseptic pharmaceuticals market size during the forecast period. Moreover, the rising population of diabetics, urinary catheters, and generic populations are likely to increase the adoption of urinary antibacterial and antiseptic pharmaceuticals during the forecast period.
E. coli and S. aureus are the causes of urinary infections, and the growth of these infections is likely to surge the market growth in recent years. The adoption of urinary antibacterial drugs such as penicillin, ciprofloxacin, and others is likely to flourish the demand for urinary antibacterial and antiseptic pharmaceuticals during the foreseen time.
However, the urinary antibacterial and antiseptic pharmaceutical treatment depend on the patient's health, history, and types of infectious bacteria. According to NIH, urinary tract infection is the most common infection, and nearly 8.1 million patients have been suffering globally in recent years. These patients are consulting with a physician, which is likely to increase the urinary antibacterial and antiseptic pharmaceuticals market growth. According to the Centers for Disease Control and Prevention report, patients suffering from urinary tract infections are acquired in 75% of hospitals globally.
Based on product type, the market is further categorized into antibacterial and antiseptic during the forecast period. However, the antibacterial product is likely to dominate the global market share by registering a significant share as it has been the primary treatment for urinary tract infections in recent years.
Based on distribution channels, the market is subdivided into hospital pharmacies, e-commerce, and pharmacy & drugstores during the foreseen time. In these, hospital pharmacies dominate the global market by capturing a higher share during the forecast period.
Based on region, Europe is estimated to lead the urinary antibacterial and antiseptic pharmaceuticals market by securing a relevant share during the forecast period. On the other hand, the prominent players are making efforts to develop the best antibiotics for urine infection and urinary antiseptic drugs to help patients recover fast in the region.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The R&D activities and rising healthcare specialists are likely to propel the market size in recent years. The key vendors are making several marketing methodologies to acquire the maximum share of the market, such as mergers, acquisitions, collaborations, and product launches.
Urinary tract infection refers to bacterial infection in any part of urinary system such as urethra, ureters, bladder and kidney. Urinary tract infections are common in patients which are using urinary catheter, diabetics and elderly people having compromised immunity.
Most of the urinary infections are caused by E. coli and S. aureus. Urinary tract infections are mostly treated with antibacterial drugs such as ciprofloxacin, azithromycin, penicillin and others. Urinary antiseptics such as nalidixic acid, nitrofurantoin etc.
can also be effectively used for management of urinary tract infections, these are the drugs which are excreted in urine and show their antiseptic action in the bladder. The choice of treatment depends on type of infectious bacteria and patient history, complicated urinary tract infections leads to kidney damage and may need hospitalization.
According to National Institute of Diabetes, Digestive and Kidney Diseases (NIH), urinary tract infection is the second most common type of infection and approximately 8.1 Mn patients visit every year to their physician concerning urinary tract infection.
Increasing recurrence rate for urinary tract infections is the major driver for the growth of urinary antibacterial and antiseptic pharmaceuticals market. Other factors influencing growth of urinary antibacterial and antiseptic pharmaceuticals market can be increasing incidence of diabetes, rising cases of catheter-associated urinary tract infections and expanding indications of drugs, availability of combination products, etc.
According to Center for Disease Control and Prevention (CDC), 75% of the hospital acquired urinary tract infections are associated with the catheter use. Major restraint for growth of global market for urinary antibacterial and antiseptic pharmaceuticals is increasing bacterial resistance to antibiotics.
The global urinary antibacterial and antiseptic pharmaceuticals market is expected to witness sluggish growth due to huge competition between generic players in major markets. Antibacterial product segment is anticipated to hold maximum market as it is the first line treatment for urinary tract infections.
Hospital end user segment will continue to lead the global market for urinary antibacterial and antiseptic pharmaceuticals market due to increasing usage of urinary catheters among patients. According to CDC data, 15-25% of all hospitalized patients require catheter use during their hospital stay.
Several new treatment options such as monoclonal antibodies are being developed for infection which can influence the market.
Geographically, the global urinary antibacterial and antiseptic pharmaceuticals market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa.
Europe is anticipated to lead the global market for urinary antibacterial and antiseptic pharmaceutical due to greater incidence community acquired urinary tract infections, followed by North America. However, the market is expected to register decline in revenue in the regions of North America and Europe.
The Asia Pacific market for urinary antibacterial and antiseptic pharmaceuticals is anticipated to exhibit moderate growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some of the key market players in global urinary and antiseptic pharmaceuticals market are Pfizer Inc., AstraZeneca Plc., Merck & Co., GlaxoSmithKline Plc., Bayer Pharma AG, Johnson & Johnson Private Limited, Daiichi Sankyo Company Limited and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, type of product and applications.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The global urinary antibacterial and antiseptic pharmaceuticals market is classified on the basis of product type, distribution channel and geography.